⌘K
Loading ticker…
As of 2026-08-24, Vaxcyte, Inc. Common Stock (PCVX) has a 3-month relative strength percentile of 88 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 61. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.1%, relative volume 0.69×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PCVX is in a stage 2 uptrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 9.7% / 16.0%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
PCVX is held by 32 ETFs as of May 2026. Top owner: VTWO at 0.19% weight, $33M notional. Top 3 carry $83M.
Held by 80 ETFs · $1.2B across latest filings · largest weight 4.64% (MEDI).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.19% | $33M | −0.06 pp |
| SCHASchwab U.S. Small-Cap ETF | 0.14% | $32M | −0.05 pp |
| VHTVanguard Health Care ETF | 0.10% | $18M | −0.01 pp |
| SCHMSchwab U.S. Mid-Cap ETF | 0.12% | $18M | −0.04 pp |
| VTWV | 0.40% |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| $5M |
| −0.12 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.01% | $4M | — |
| VFMO | 0.20% | $4M | new |
| ESML | 0.12% | $3M | −0.03 pp |
| MSSM | 0.26% | $2M | −0.21 pp |
| ONEQ | 0.02% | $2M | — |
Showing 10 of 32 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PCVX Jan avg: 8.08% median: 10.81% win: 75% σ: 9.64% n: 4 2022-04-12 → 2026-07-31 | PCVX Feb avg: -2.09% median: -3.15% win: 50% σ: 14.37% n: 4 2022-04-12 → 2026-07-31 | PCVX Mar avg: -17.54% median: -7.99% win: 0% σ: 20.53% n: 4 2022-04-12 → 2026-07-31 | PCVX Apr avg: -1.20% median: -2.34% win: 20% σ: 9.48% n: 5 2022-04-12 → 2026-07-31 | PCVX May avg: 2.24% median: -0.91% win: 40% σ: 12.93% n: 5 2022-04-12 → 2026-07-31 | PCVX Jun avg: 2.43% median: 0.85% win: 80% σ: 8.43% n: 5 2022-04-12 → 2026-07-31 | PCVX Jul avg: 0.85% median: 4.43% win: 60% σ: 5.82% n: 5 2022-04-12 → 2026-07-31 | PCVX Aug avg: 3.61% median: 5.20% win: 75% σ: 9.71% n: 4 2022-04-12 → 2026-07-31 (current) | PCVX Sep avg: 12.10% median: 7.59% win: 50% σ: 22.33% n: 4 2022-04-12 → 2026-07-31 | PCVX Oct avg: 23.71% median: 10.03% win: 50% σ: 41.51% n: 4 2022-04-12 → 2026-07-31 | PCVX Nov avg: 2.88% median: 6.62% win: 75% σ: 9.59% n: 4 2022-04-12 → 2026-07-31 | PCVX Dec avg: 1.30% median: -1.45% win: 50% σ: 15.14% n: 4 2022-04-12 → 2026-07-31 |